Cancer Institute A national cancer institute
designated cancer center

Hodgkins Lymphoma Expertise

Pediatric Oncology Program

For information on our Pediatric Oncology Program please visit Lucile Packard Children's Hospital.

For Physicians: To refer a pediatric patient, please call (650) 725-1072.

The Stanford Lymphoma Program is world renowned for ground-breaking developments in the treatment of Hodgkin lymphoma. Our team of experts is focused on advancing the treatment of Hodgkin lymphoma with over 50 years of extensive expertise in the management of patients, both adults and children, with Hodgkin lymphoma. Our team has 50 years of extensive expertise in the management of patients with Hodgkin lymphoma.

Our weekly tumor board dedicated to patients with Hodgkin lymphoma allows our experts to collectively discuss all cases and review imaging studies and pathology results in order to define and individualize optimal treatment plans for each patient.

Precedent Setting Contributions
There is a rich history of faculty at Stanford University having made major contributions  leading to the cure of Hodgkin lymphoma. The late Dr. Henry S. Kaplan co-designed the first linear accelerator - now the backbone of radiation therapy for cancer worldwide.  Dr. Kaplan, along with Dr. Saul Rosenberg, conducted clinical trials over several decades, which led to an ever-increasing cure rate for this disease.

Recognition of therapy related late effects led investigators at Stanford to pioneer the systematic refinements of radiation therapy fields and doses.

Over the past two decades, clinical researchers in the Hodgkin lymphoma program have focused on diminishing long-term toxicity among patients, while further improving the cure rate. With the Stanford V regimen, greater than 90% of patients are cured with fertility preserved.

For the minority of patients who experience relapsed or refractory disease, other treatments may include stem cell or bone marrow transplantation. Recent innovations include the non-myeloablative allogeneic transplant, an outpatient procedure with limited side effects and minimal need for hospitalization. Additionally, Stanford researchers are involved in the exploration of promising new targeted agents for these patients.  Stanford participated in the evaluation of brentuximab vedotin (SGN-35), an antibody-drug conjugate recently approved by the Food and Drug Administration (FDA) for patients who relapse after an autologous stem cell transplant.We continue to study key research questions, such as why disease relapses (returns following remission) or becomes highly refractory (resistant and does not respond to primary treatment).

In pediatric patients, the Stanford team pioneered the use of low dose, involved field radiation plus chemotherapy to minimize early and late effects of therapy.

Learn more about our current clinical trials.

Stanford Medicine Resources:

Footer Links: